The results indicate that pRB, pAkt, and pS6 may synergistically regulate cancer cell survival, and their simultaneous suppression could be critical for achieving optimal anti-tumour activity with the combination of Alpelisib and Ribociclib in CRC. Here, RB1 is linked to cancer.